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ABSTRACT:
Preclinical studies demonstrate that epidermal growth factor receptor (EGFR) 
signals through both kinase-dependent and independent pathways and that combining 
a small-molecule EGFR inhibitor, EGFR antibody, and/or anti-angiogenic agent is 
synergistic. We conducted a dose-escalation, phase I study combining erlotinib, 
cetuximab, and bevacizumab. The subset of patients with metastatic colorectal 
cancer was analyzed for safety and antitumor activity. Forty-one patients with 
heavily pretreated metastatic colorectal cancer received treatment on a range of 
dose levels. The most common treatment-related grade ≥2 adverse events were 
rash (68%), hypomagnesemia (37%), and fatigue (15%). Thirty of 34 patients 
(88%) treated at the full FDA-approved doses of all three drugs tolerated treatment 
without drug-related dose-limiting effects. Eleven patients (27%) achieved stable 
disease (SD) ≥6 months and three (7%) achieved a partial response (PR) (total 
SD>6 months/PR= 14 (34%)). Of the 14 patients with SD≥6 months/PR, eight 
(57%) had received prior sequential bevacizumab and cetuximab, two (5%) had 
received bevacizumab and cetuximab concurrently, and four (29%) had received 
prior bevacizumab but not cetuximab or erlotinib (though three had received prior 
panitumumab). The combination of bevacizumab, cetuximab, and erlotinib was well 
tolerated and demonstrated antitumor activity in heavily pretreated patients with 
metastatic colorectal cancer. 
INTRODUCTION
Epidermal growth factor receptor (EGFR) plays 
an important role in tumorigenesis [1] and signals via 
downstream effectors [2]. EGFR protein is overexpressed 
in 35 to 49% of patients with colorectal cancer [3-5] 
with a higher percentage of EGFR overexpression in late 
stage colorectal tumors [6]. Cetuximab, a monoclonal 
antibody that binds to EGFR [7,8], is approved by the 
Food and Drug Administration (FDA) for K-Ras wild 
type metastatic colorectal cancer [9]. Erlotinib, a tyrosine 
kinase inhibitor of EGFR [10], is approved for locally 
advanced or metastatic non-small cell lung cancer and 
locally advanced, unresectable, or metastatic pancreatic 
cancer, but is not currently FDA-approved for colorectal 
cancer.
Recently, Weihua et al. [11] discovered that EGFR 
can maintain cancer cell survival independent of its 
kinase activity. This kinase-independent pathway operates 
via increased glucose uptake due to stabilization of the 
SGLT1 glucose transporter, with a downstream effect of 
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reduced autophagy [11].  Furthermore, preclinical studies 
revealed that combining antibodies and kinase inhibitors 
was synergistic in lung and head and neck cancer cell lines 
[12], as well as in lung xenografts [12], and an EGFR-
dependent human xenograft model [13].  The combination 
of cetuximab and erlotinib synergistically inhibits growth 
of colon cancer cell lines, and has shown antitumor 
activity in patients with metastatic colorectal cancer [14]. 
Angiogenesis plays an important role in tumor 
development and metastasis [15], and is partly mediated 
by vascular endothelial growth factor (VEGF) [16]. 
Bevacizumab is a recombinant anti-VEGF monoclonal 
antibody FDA-approved for treatment of metastatic 
colorectal cancer in combination with 5-fluorouracil-
based chemotherapy [9]. Multiple studies combining 
chemotherapy and bevacizumab have demonstrated 
increased efficacy versus chemotherapy alone [17-19]. 
The addition of bevacizumab to chemotherapy regimens 
has increased overall survival [17], increased median 
progression-free survival [18], and improved response 
rate with longer duration of survival [19] in patients with 
colorectal cancer.
Anti-VEGF treatment used in conjunction with 
EGFR inhibitors has shown promise in preclinical and 
clinical studies. A xenograft study blocking VEGF 
and EGFR demonstrated synergistic antitumor activity 
[20], and mice intraperitoneally injected with human 
colon cancer cells showed improved antitumor activity 
in response to cetuximab and an anti-VEGF receptor 
2 antibody [21]. Phase I and II clinical studies indicate 
increased efficacy with the combination of anti-VEGF and 
anti-EGFR therapy, with improved response rate, increased 
time to progression, and increased overall survival in 
patients who received cetuximab and bevacizumab [22] 
versus historical control groups of patients who received 
cetuximab [23], bevacizumab monotherapy [24], or 
cetuximab plus chemotherapy [25]. This activity of the 
combination of cetuximab and bevacizumab may be due 
to the fact that resistance to EGFR inhibitors is mediated, 
at least partly, by activating VEGF-dependent signaling 
[26,27].
Here, we report, for the first time, the results of 
administering dual EGFR inhibition (erlotinib plus 
cetuximab) together with an anti-angiogenic agent 
(bevacizumab) in patients with heavily-pretreated 
colorectal cancer.
RESULTS
Demographics
Forty-one patients with colorectal cancer were 
enrolled (Table 2). All patients had progressive disease 
at the time of enrollment. Most patients were heavily 
pretreated, with a median of five prior therapies (range, 
2-12). Thirty-eight patients (93%) had previously received 
bevacizumab; 33 patients (80%), cetuximab; and one 
patient (2%) had received no prior study drugs. 
Adverse Events
The most common treatment-related grade 
2 or higher adverse events were rash (n=28, 68%), 
hypomagnesemia (n=18, 44%), fatigue (n=6, 14%), 
diarrhea (n=5, 12%), and hyperbiliruemia (n=4, 10%) 
(Table 1). Eight patients (20%) experienced no drug-
related toxicity higher than grade 1. Seventeen patients 
(41%) required a dose reduction because of toxicity, 
including cetuximab in 13 patients for rash, two patients 
for diarrhea, one patient for hypomagnesemia, and one 
patient for diarrhea and transaminitis. Two patients (5%) 
withdrew due to toxicity, including grade 2 skin rash in 
cycle 1 (n=1) and grade 2 diarrhea and fatigue in cycle 
1 (n=1). No deaths resulted from adverse events. The 
RP2D was level 8, which include the recommended FDA-
approved full doses of each medication [28].
Responses and time to treatment failure
In total, SD≥6 months or PR was achieved in 14 
patients (34%) (Figure 1). The overall confirmed response 
rate was 7% (PR). Eleven patients (27%) achieved stable 
disease (SD) lasting at least 6 months (duration was 6, 6, 
6, 6, 6, 6, 6+, 7+, 8+, 10 and 10 months). Three patients 
(7%) achieved a PR and received treatment for 4, 6+, and 
21 months (Table 3, Figure 2). Two patients withdrew 
before the first restaging assessment due to toxicity, 
and one patient withdrew early because of financial 
considerations. However, all patients were considered 
eligible for evaluation of response. Exploratory analysis 
of genomic aberrations was performed in selected patients 
who had tissue available (Table 4).
Median time to treatment failure for the current 
treatment is 3.3 months with 95% CI = (2.1, 4.4), while 
for the immediately prior standard treatment, the median 
is 3.0 (2.0, 6.0). (p=.71) (Figure 3).
Prior EGFR inhibitor or VEGF Inhibitor Therapy 
and Response
Of 41 patients on study, a total of 38 patients (93%) 
had received prior bevacizumab, and a total of 33 patients 
(80%) had received prior cetuximab (Table 2). Thirty-
one patients (76%) had received prior bevacizumab and 
prior cetuximab (27 sequentially, 4 concurrently), seven 
patients (17%) had received prior bevacizumab and no 
other study drugs, and two patients (5%) had received 
prior cetuximab and no additional study drugs. No 
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patients had received prior erlotinib. Four patients had 
previously received panitumumab, a monoclonal antibody 
that binds to EGFR and inhibits epidermal growth factor 
autocrine signaling. 
Prior bevacizumab and cetuximab, even if given 
concurrently, did not preclude SD≥6 months/PR. Four of 
the seven patients (56%) who received prior bevacizumab 
and no other prior study drugs achieved SD≥6 months/
PR; three of these four patients had also received prior 
panitumumab. Of the 38 patients who had received prior 
bevacizumab, 14 (37%) achieved SD≥6 months/PR; of 
the 33 patients that received prior cetuximab, 10 (30%) 
achieved SD≥6 months/PR; of the 31 patients who had 
received prior cetuximab and bevacizumab, 10 (32%) 
achieved SD≥6 months/PR. The latter included four 
patients who had received prior concurrent bevacizumab 
and cetuximab, two of whom achieved SD≥6 months/
PR. Of the 14 patients with SD≥6 months/PR, eight 
(57%) had received prior sequential bevacizumab and 
cetuximab, two (5%) had received bevacizumab and 
cetuximab concurrently, and four (29%) had received 
prior bevacizumab but not cetuximab (though three had 
received prior panitumumab (Table 3 and Figure 1). 
Patient 135, who had received prior panitumumab and had 
also previously received bevacizumab, achieved a partial 
response and was on study for 21 months (Table 3). 
Dosing and Response
Of 37 patients on dose levels 7 or 8, thirteen (35%) 
achieved SD≥6 months/PR. Of the four patients treated at 
dose levels 1-6, one patient (25%) achieved SD≥6 months/
PR (Table 1 and Figure 1). There was no obvious dose-
response correlation, although the number of patients at 
lower dose levels was small.
Toxicity and Response
Rash was the most frequently observed toxicity in 
patients (Table 1). Patients with grade 2 or higher rash 
were not significantly more likely to attain SD≥6 months/
PR (two-tailed chi squared, p=0.76). Nineteen patients 
experienced grade 2 rash, of whom six (31%) achieved 
SD≥6 months/PR. Four of nine patients (44%) with grade 
3 rash achieved SD≥6 months/PR (Table 3). Of 13 patients 
with grade 1 or no rash, four (31%) achieved SD≥6 
months/PR. 
DISCUSSION
We report the results of the cohort of patients with 
colorectal cancer treated on a phase I dose-escalation trial 
of combination cetuximab, erlotinib, and bevacizumab. 
The rationale for this combination was: (1) preclinical 
and clinical studies that suggested increased activity when 
anti-VEGF therapy was combined with EGFR inhibitors 
[20,21], (2) preclinical studies indicating that EGFR 
signals through both kinase-dependent and -independent 
pathways [11], and (3) clinical trials demonstrating 
increased overall survival in patients treated with 
cetuximab and bevacizumab [22].
This combination of drugs was well-tolerated. The 
RP2D was determined to be the full FDA-approved doses 
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Figure 1: 3D-Waterfall. Best response in 38 colorectal cancer patients treated. Patients with early clinical progression or new lesions 
before first restaging are indicated arbitrarily as +21% and are marked with a “†”. Three patients who withdrew early before restaging 
because of toxicity (n=2) or financial reasons (n=1) are not depicted in the figure. Patients with progressive disease are shown in red; 
patients who achieved stable disease are shown in orange, patients who achieved stable disease of at least six months are shown in blue; 
patients who achieved partial response are shown in green. The dose level and treatment duration (months) for each patient are shown in 
the table below. Patients still on treatment have a “+” after the number of months and are indicated with an arrow (>) on the grey bar for 
that patient.
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for all three drugs [28], and 31 of the 34 patients (91%) 
treated at the RP2D tolerated treatment without drug-
related dose-limiting effects.
This regimen demonstrated antitumor activity in 
patients with colorectal cancer, including 14 patients 
(34%) who had a best overall response of SD≥6 months 
(n=11) or PR (n=3). SD≥6 months/PR was observed even 
in patients who had received prior bevacizumab and/or 
cetuximab or treated at a lower dose level.
Previous phase II/III clinical studies combining 
cetuximab and bevacizumab with cytotoxic chemotherapy 
in patients with colorectal cancer resulted in disappointing 
results [29-32]. One notable difference is that our current 
study included erlotinib dosing up to 150 mg daily, in 
contrast to 100 mg in prior studies [14]. It is conceivable 
that, in this context, the chemotherapy component of the 
above regimen may be detrimental, whereas regimens 
that combine anti-EGFR and anti-VEGF agents without 
cytotoxic chemotherapy deserve further investigation. 
Indeed, studies in pancreatic adenocarcinoma [33] and 
squamous cell carcinoma of the head and neck [34] that 
use a combination of cetuximab and bevacizumab show 
promising results. 
A prior preclinical study combining erlotinib and 
cetuximab demonstrated synergistic antitumor activity in 
colorectal cancer [14], and a related phase II clinical trial 
of this combination achieved an overall response rate of 
31% [14], which is similar to the rate of SD≥6 months/
PR observed in our study. Importantly, the phase II study 
of erlotinib and cetuximab did not report the number of 
prior systemic therapies, whereas our study included 
patients who were heavily pretreated (median of five prior 
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systemic therapies).
Remarkably, patients in our study who previously 
had failed bevacizumab and/or cetuximab were able 
to acheive SD≥6 months/PR. Recent studies suggest 
that combining EGFR kinase inhibitors and anti-EGFR 
antibodies may be more effective than either alone, 
perhaps because EGFR is able to maintain cancer cell 
survival independent of its kinase activity [11-14].  The 
clinical data presented here also support combining kinase 
inhibitors and antibodies. 
Exploratory analysis of molecular aberrations was 
performed. Of the 14 patients who achieved SD≥6 months/
PR in our study, four had mutations present (PIK3CA 
E545K (n=1), TP53 R175H and PTEN loss (n=1), TP53 
R175H (n=1), TP53 R248W (n=1). This analysis is limited 
however by the fact that only a small number of mutations 
were evaluated in individual patients.
Previous studies demonstrated a correlation between 
rash and response to EGFR inhibitors [35,36]. However, in 
our study we did not observe a trend of higher grade rash 
in patients with SD≥6 months/PR (p=0.76).  Larger studies 
could have more definitive conclusions in this regard.
There are several limitations to this study. First, 
molecular correlates could only be obtained in a small 
subset of patients, precluding a robust analysis. Second, 
these patients had a median of five prior therapies in the 
metastatic setting, perhaps attenuating their ability to 
respond. Third, determination of time to treatment failure 
of prior therapy was obtained from chart review, rather 
than prospectively.
In conclusion, the results presented here demonstrate 
that dual inhibition of EGFR with erlotinib and cetuximab, 
combined with the VEGF antibody bevacizumab, is well-
tolerated, allowing full doses of all three drugs in patients 
with colorectal cancer. The most common side effect 
is rash. SD≥6 months/PR was achieved in 34% of this 
heavily pretreated patient population, including patients 
treated with prior bevacizumab and/or cetuximab. These 
findings merit further investigation in a larger study of 
patients with metastatic colorectal cancer.
METHODS
Study Design
This report is a subset analysis of a larger phase 
I study of combination cetuximab, erlotinib, and 
bevacizumab. The study was conducted at The University 
of Texas M. D. Anderson Cancer Center (MDACC) per 
Institutional Review Board guidelines. The colorectal 
Figure 2: Computerized tomography (CT) 
demonstrating response to treatment with 
combination cetuximab, erlotinib, and 
bevacizumab in a patient with KRAS wild-
type colorectal cancer who had received 
prior cetuximab and bevacizumab. A 
decrease in tumor size of 45% by RECIST was 
observed, and the patient received treatment for 6 
months. Panel A demonstrates a liver metastasis at 
baseline, and Panel B demonstrates the tumor after 
6 months of treatment.
Figure 3: Kaplan-Meier curve for time 
to treatment failure for the current study 
versus the immediately prior standard 
therapy.
Oncoscience547www.impactjournals.com/oncoscience
cancer cohort reported herein included all patients with 
colorectal cancer who started therapy between 12/10/2007 
and 5/7/2012 as part of a dose-escalation study conducted 
in patients with advanced cancer. The dose escalation 
portion of the study determined the recommended phase 
II dose (RP2D) to be bevacizumab 10 mg/kg IV every two 
weeks; cetuximab loading 400 mg/m2, maintenance 250 
mg/m2 IV weekly; and erlotinib 150 mg PO daily on a 28 
cycle [28]. Patients were treated at variable dose levels, 
depending on the time of study entry (Table 1).
Patients
Patients had metastatic or advanced colorectal 
cancer not amendable to standard therapy, an Eastern 
Cooperative Oncology Group (ECOG) performance 
status 0-2 [37], and adequate hematologic, hepatic, and 
renal function. Exclusion criteria included hemoptysis, 
unexplained bleeding, significant cardiovascular 
disease, intercurrent uncontrolled illness, significant 
gastrointestinal bleeding within 28 days, hemorrhagic 
brain metastases, prior abdominal surgery within 30 
days, pregnancy, and a history of hypersensitivity to 
bevacizumab, cetuximab, and/or erlotinib. Treatment with 
prior cytotoxic therapies must have ended at least three 
weeks prior to enrollment, and biologic therapy must have 
either ended at least two weeks or five drug half-lives prior 
to enrollment, whichever was shorter. Patients may have 
received an unlimited number of prior therapies, including 
prior anti-EGFR and anti-angiogenic agents. 
Safety
Clinically significant adverse events were assessed 
according to the National Cancer Institute Common 
Terminology Criteria for Adverse Events (NCI CTCAE), 
version 3.0. History, physical exam, hematology, blood 
chemistry, and urinalysis were performed at baseline and 
regular intervals while receiving treatment.
Evaluation of Efficacy
Treatment efficacy was evaluated by diagnostic 
imaging per Response Evaluation Criteria in Solid 
Tumors (RECIST) 1.0 [38]. Radiologic assessments were 
conducted at baseline and about every 8 weeks thereafter.
Molecular Testing
EGFR, KRAS, PIK3CA, p53, and BRAF 
mutation analysis, as well as PTEN expression by 
immunohistochemistry, were performed in the Clinical 
Laboratory Improvement Amendments (CLIA)-approved 
MDACC laboratory for patients with available archived 
tissue (supplementary methods). 
Statistical Analysis
Analyses were descriptive and exploratory. 
Correlational statistics were determined by Spearman’s 
correlation and dichotomous variables were evaluated with 
chi-square or Fisher’s exact test. We estimated the time 
to treatment failure distribution using the Kaplan-Meier 
product limit method, and estimation of 95% confidence 
interval for the mean was calculated using conventional 
methods (mean +/- 2*SEM where SEM = standard error 
of the mean). Time to treatment failure was defined as the 
duration of treatment received until a patient developed 
progressive disease or withdrawal from study because of 
toxicity or any other reason.
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